The main purpose of this study is to evaluate the safety of an investigational CAR-T cell therapy called Descartes-08. The study will also explore whether Descartes-08 provides any treatment benefit in patients with Multiple Myeloma.

SparkCures ID	943
Trial Phase	Phase 1
Enrollment	38 Patients
Treatments	Descartes-08
Tags	B-Cell Maturation Antigen (BCMA) CAR T Cell
Trial Sponsors	Cartesian Therapeutics
NCT Identifier	NCT03448978

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria (condensed):

Multiple myeloma that is double-refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) after at least 2 prior lines of therapy OR have failed at least 3 prior lines of therapy
Measurable disease activity as indicated by serum or urine M-protein, serum free light chain, biopsy-proven plasmacytoma, >5% bone marrow plasma cells.
Adequate vital organ function as indicated by ANC (>1000/uL), platelet count (>50,000/uL), hemoglobin (>8 g/dL), serum ALT and AST (each < 2.5 3.0 x upper limit of normal), total bilirubin (<2 mg/dL), creatinine clearance (> 60 30 mL/min), and cardiac ejection fraction (> 50 45%)

Exclusion Criteria (condensed):

Plasma cell leukemia
Pregnant or lactating
Active, uncontrolled infection
Active and severe auto-immune disease
Active arrhythmia, or obstructive or restrictive pulmonary disease
Central nervous system disease

SparkCures Verified

SparkCures is working closely with Cartesian Therapeutics to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors

Study of CD8+ anti-BCMA CAR T-cells in Patients with Multiple Myeloma

Overview

Am I Eligible?

US Trial Locations